RAPT

In a report released on December 8, Thomas Smith from SVB Securities reiterated a Buy rating on RAPT Therapeutics (RAPT - Research Report). The company's shares closed last Friday at $17.06.According to TipRanks, Smith is a 4-star analyst with an average return of 4.8% and a 41.48% success rate. Smith covers the Healthcare sector, focusing on stocks such as Immunic, Provention Bio, and Keros Therapeutics.The word on The Street in general, suggests a Strong Buy analyst consensus rating for RAPT Therapeutics with a $42.33 average price target, representing a 148.12% upside.
https://www.tipranks.com/news/blurbs/svb-securities-keeps-their-buy-rating-on-rapt-therapeutics-rapt-2?utm_source=advfn.com&utm_medium=referral